Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022
CPRIT grant to support majority of 186RNL targeted therapeutic development costs for leptomeningeal metastases program over three years; extends expected Company cash runway through 2025
Related news for (PSTV)
- Silk, Cells, and Sudden Swings
- Today’s Top Performers: MoBot’s Market Review 09/26/25 09:00 AM
- Power Hour Pulse: Spider Silk Surge and Biotech Beats Drive Afternoon Frenzy – These Microcaps Could Explode into Close
- From Web3 to Quantum: Small-Cap Innovators OFAL, SPRC, XXII Lead Market Movers as XHLD Builds Visibility
- MoBot’s Stock Market Highlights – 09/25/25 08:00 AM